A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat Following BRAF and MEK Inhibitors in BRAF^V600 mutated Melanoma

Scientists assessed the anti-tumor activity of sequential treatment with vorinostat following BRAF and MEK inhibitors (BRAFi/MEKi) in patients with BRAFV600 melanoma who progressed after initial response to BRAFi/MEKi.